Royalty Pharma: Identifying and Investing in Future Fields of Biopharma Innovation! 

Within the first quarter of 2024, Royalty Pharma displayed impressive performance, managing 14% growth in royalty receipts, thereby underlining the benefits of its diversified portfolio encompassing over 35 commercial products. However, it is important to note a decline for milestones and other contractual payments, which were mainly affected by a high base of the year-ago quarter due to a single nonrecurring Biohaven-related payment. Portfolio Receipts, as a result, decreased to $717 million, aligning with the company’s expectations. For capital allocation, Royalty Pharma announced a transaction that is expected to raise its capital deployment to approximately $670 million, involving the acquisition of royalties and milestones on Sanofi’s frexalimab, costing approximately $525 million, which includes estimated transaction costs. Sanofi’s frexalimab is an exciting development stage drug with potential multi-blockbuster opportunities in multiple sclerosis and other immune indications.